/

Other

/

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals

Verified Nov 2026

Other

·

United States flag

Conshohocken, Pennsylvania

·

Since 2016

Madrigal Pharmaceuticals is a biopharmaceutical company headquartered in Conshohocken, Pennsylvania, founded in 2016, with 500–1,000 employees and estimated revenue of $500 million to $1 billion. The company develops small-molecule therapeutics for cardiovascular, metabolic, and liver diseases. Its lead product, Rezdiffra, is the first FDA-approved treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with moderate-to-severe liver fibrosis.

Madrigal Pharmaceuticals

Verified Nov 2026

AT A GLANCE

Founded

2016

Headquarters

United States flag

Conshohocken, Pennsylvania

Employees

500-1,000

Ownership

Madrigal Pharmaceuticals at a glance

Revenue

$500M-1B

Est. band

Employees

500-1,000

Founded

2016

Headquarters

Conshohocken, Pennsylvania

Industries

Automotive

Electric Vehicles

Medical

Overview

Madrigal Pharmaceuticals is a biopharmaceutical company headquartered in Conshohocken, Pennsylvania, founded in 2016, with 500–1,000 employees and estimated revenue of $500 million to $1 billion. The company develops small-molecule therapeutics for cardiovascular, metabolic, and liver diseases. Its lead product, Rezdiffra, is the first FDA-approved treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with moderate-to-severe liver fibrosis.

At a glance

Attribute

Detail

Founded

2016

Headquarters

Conshohocken, Pennsylvania

Employees

500-1,000

Revenue

$500M-1B (estimated)

What Madrigal Pharmaceuticals makes

The company's capabilities include drug discovery, small-molecule therapeutic development, clinical trial execution, and regulatory pathway navigation for liver fibrosis and metabolic disease treatments.

Latest developments

Company details

Madrigal is a privately held biopharmaceutical firm with a team of approximately 528 employees focused on advancing metabolic health management and early diagnosis and treatment of liver diseases. Madrigal Pharmaceuticals was founded in 2016, has an estimated 500-1,000 employees, and is headquartered in Conshohocken, Pennsylvania.

Frequently asked questions

What does Madrigal Pharmaceuticals do?

Madrigal Pharmaceuticals is a biopharmaceutical company headquartered in Conshohocken, Pennsylvania, founded in 2016, with 500–1,000 employees and estimated revenue of $500 million to $1 billion. The company develops small-molecule therapeutics for cardiovascular, metabolic, and liver diseases. Its lead product, Rezdiffra, is the first FDA-approved treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with moderate-to-severe liver fibrosis.

Where is Madrigal Pharmaceuticals headquartered?

Madrigal Pharmaceuticals is headquartered in Conshohocken, Pennsylvania (200 Barr Harbor Drive, Conshohocken, Pennsylvania, 19428).

When was Madrigal Pharmaceuticals founded?

Madrigal Pharmaceuticals was founded in 2016.

How big is Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals has an estimated 500-1,000 employees, with revenue in the $500M-1B range (estimated).

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

Conshohocken, Pennsylvania (HQ)Headquarters · United States
Conshohocken, Pennsylvania (HQ)200 Barr Harbor Drive, Conshohocken, Pennsylvania, 19428, United StatesHeadquarters

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.